AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

Mon, August 10, 2026 at 7:59 PM GMT+3 3 min read

• ABBV -0.34%

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the first and only neurotoxin approved for that use in the US and the fifth aesthetic indication for a drug that already anchors AbbVie's fastest-growing units.

Bull Case: A Pipeline That Keeps Finding New Uses

The filing rests on two Phase 3 studies, M21-416 and M21-417, both of which hit their main goal and showed statistically significant improvement in masseter prominence against a placebo, with p-values of 0.0046 and 0.0014. Twice as many treated patients called themselves satisfied compared with the placebo group, and the safety data lined up with Botox's long track record, with no new red flags. That is the AbbVie playbook in miniature: squeeze another approved use out of a drug it already owns rather than starting from zero.

The broader business backs that pattern up. In the quarter ended June 30, net revenue came in just under $17 billion, up more than 10% year over year, with immunology sales climbing 15% on Skyrizi and Rinvoq and neuroscience revenue jumping more than 20%. Management raised its full-year outlook for the second time this year, and the Humira patent-cliff drag that weighed on results for two years now looks largely behind the company.

Bear Case: The Debt And Distributor Risk Underneath

Most of AbbVie's US product sales still flow through just three wholesale distributors, McKesson, Cardinal Health, and Cencora, a concentration that leaves the company exposed if any one relationship sours. The balance sheet carries real leverage too: a debt-to-equity ratio of roughly -21.1x as of its December 2025 filing means liabilities outweigh shareholder equity outright, and a current ratio near 0.7x offers less short-term cushion than many healthcare peers hold.

Patent protection for Skyrizi and Rinvoq remains a multi-year risk, and the Inflation Reduction Act already allows government price negotiation on products including Imbruvica and, notably, Botox itself. The pending $10.9 billion Apogee Therapeutics acquisition adds fresh debt and integration risk on top of that. Oncology revenue slipped almost 2% in the latest quarter, and the stock's 8% gain this year has trailed the S&P 500's 13%, with a trailing P/E near 70 that mostly reflects acquisition-related charges rather than the underlying business.

What The Market Is Pricing In

Hedge fund ownership rose from 84 funds to 87 in the most recent quarter, which points to institutions adding rather than trimming. Short interest sits at just 1.42% of float, a thin figure that suggests little organized betting against the stock. Shares currently trade at a forward P/E of 17.51, a multiple that prices in steady growth without assuming anything extraordinary. Taken together, the numbers describe a stock that funds keep buying into while few are positioned against it.

Where This Leaves Investors

The masseter filing is a small piece of a much larger machine, one where immunology and neuroscience are doing the heavy lifting while a leveraged balance sheet and distributor concentration sit in the background. For the growth case to keep compounding, Skyrizi, Rinvoq, and the neuroscience portfolio need to keep outrunning whatever pricing pressure the IRA eventually applies.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.

Disclosure: None. Follow Insider Monkey on Google News.